skip to main content

Rogel Cancer Center Members Attend 2024 ASCO Annual Meeting

Date Visible: 
05/22/2024 - 12:00pm

Media contact: Eric Olsen, 734-764-2220 |  Patients may contact Cancer AnswerLine™ 800-865-1125

Rogel Cancer Center faculty and trainees will attend, present and hold poster sessions at the American Society of Clinical Oncology meeting.

ASCO 2024 Annual Meeting Logo
Courtesy ASCO

Check out the list of U-M presenters to support your colleagues. Connect with researchers on X/Twitter using #AACR24. Be sure to tag @UMRogelCancer.

Presenter information is sometimes incomplete. If your session is missing, please email the abstract link to [email protected].

*All times are in CDT*

May 31

Breast Cancer—Local/Regional/Adjuvant; Norah Henry, chair/moderator
2:45 PM – 4:15 PM
E451 | On Demand

June 1

June 2


Professional Coach: Building the Foundation; Jennifer J. Griggs, presenter
7:30 AM – 9:30 AM
S103 | On Demand

The Place of E-Cigarettes in Smoking Cessation Treatment and Policy: Approaches From Around the World; Kenneth E. Warner, presenter
8:00 AM – 9:15 AM
S402 | On Demand

Shake It Off: Can Less Be More?; Shitanshu Uppal, presenter
9:48-10:00 AM
Hall D2 | Live Stream


Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial. Charles B Nguyen, presenter
Poster Bd #: 304b
Hall A | On Demand

Predictors of long-term prostate cancer mortality in men continuing prostate-specific antigen screening after age 70. Dana H. Chung, presenter
Poster Bd #: 346
Hall A | On Demand

Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC). Charles B Nguyen, presenter
Poster Bd #: 491
Hall A | On Demand

Clinical outcomes in salivary adenoid cystic carcinoma. Prarthana Dalal, presenter
Poster Bd #: 418
Hall A I On Demand

Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial. Paul Swiecicki, presenter
Poster Bd #: 430b
Hall A I On Demand

Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy. Francis P. Worden, presenter
Poster Bd #: 414
Hall A I On Demand

June 3


An Update on the Fatigue SIO/ASCO Guidelines; Suzanna M. Zick, presenter
8:00-8:15 AM
S102 | On Demand

Navigating Therapeutic Dilemmas in Advanced Hepatocellular Carcinoma: Cases and Considerations; Baljendra Kapoor, presenter
11:30 AM – 12:30 PM
E451 | On Demand

Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.; Ulka N. Vaishampayan, presenter
1:50-2:02 PM
Hall D2 | Live Stream

Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.; Erin Frances Cobain, presenter
5:00-5:12 PM
Hall B1 | Live Stream


Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Yasmin Karimi, presenter
Poster Bd #: 15
Hall A | On Demand

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Yasmin Karimi, presenter
Poster Bd #: 22
Hall A | On Demand

Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study. Henry Dumke, presenter
Poster Bd #: 64
Hall A | On Demand


Attitudes and engagement about cascade genetic testing in a population-based cohort of women diagnosed with cancer. Steven Jay Katz, presenter
Poster Bd #: 116
Hall A | On Demand

Association of social determinants of health (SDH), allostatic load (AL) and incident cancers in the multi-ethnic study of atherosclerosis (MESA). Ruth C. Carlos, presenter
Poster Bd #: 89
Hall A | On Demand

Impact of chemotherapy-induced peripheral neuropathy permanence on patients' preference to discontinue chemotherapy. Daniel Louis Hertz, presenter
Poster Bd #: 175
Hall A | On Demand